Pharmacological interventions that attenuate CRM1 activity reduce neuronal death and restore nucleocytoplasmic transport in either a model of Huntington's disease [39], a model of amyotrophic lateral sclerosis and frontotemporal dementia [42], and a Drosophila model of tauopathies [40]. This evidence concerns the gene XPO1 and Huntington disease.